SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC
Status:
NOT_YET_RECRUITING
Trial end date:
2028-07-30
Target enrollment:
Participant gender:
Summary
This is a Phase II study of anti-nectin-4 ADC combined with the EGFR monoclonal antibody and the PD-1 monoclonal antibody in participants with advanced head and neck squamous cell carcinoma.